Abstract 3577
Background
Triple-negative breast cancer (TNBC) is the most aggressive among breast cancer subtypes, as these tumors frequently develop resistance to the treatment used. External signals provided by the surrounding tumor microenvironment (TM), which in mammary tumors is mainly constituted by adipose tissue (AT), control this resistance. Therefore, therapies that targets not only the cancer bulk but also its surrounding TM may be more effective. Preliminary in vitro and in vivo studies using mesenchymal stem cells from TNBC patient’s AT (MSCTNBC) showed how a conditioned medium (CM) prepared from MSCTNBC (MSCTNBC-CM) promoted tumorigenicity, invasion, and chemoresistance. In the present work, molecular mechanism will be investigated to identify novel druggable targets in TNBC.
Methods
TNBC cells (MDA-MB-231, BT549, and HS578T) were exposed to MSCTNBC-CM. The activation profile of tyrosine kinase receptors (RTKs) was evaluated using a commercial array. The effect of the inhibitors in the absence and presence of MSCTNBC-CM on TNBC cells recurrence potential, invasion, and cell death were evaluated in vitro through clonogenic, matrix invasion, and flow cytometry assays. Impact on tumour growth was evaluated in a MSCTNBC-TNBC preclinical model (BALB-nu mice).
Results
RTKs activation profile in response to MSCTNBC-CM revealed that TM secreted factors activates Src protein family (SFK) in TNBC. The use of the SFK inhibitor Dasatinib, both in vitro and in vivo, showed a marked reduction of invasion and recurrence potential, an induction of cell death, and a lower of tumour growth.
Conclusions
In this study, we describe SFK as mediators in the communication within the tumour adipose niche and provides fundamental information to understand TNBC progression, as well as its behavior in response to chemotherapy. The specific blockade of the SFK signaling pathway with Dasatinib can interrupt this communication and revert TM protective effect, resulting in death and smaller tumour size. Our results open the gate to the development of new strategies targeting TM to treat TNBC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Diputación de Albacete.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2273 - High performance of serial tumor biopsies in first in human (FIH) phase I trials.
Presenter: Jun Sato
Session: Poster Display session 1
Resources:
Abstract
5933 - Response rates and lesion-level progression patterns of solid tumor patients in an academic phase 1 program: implications for tumor heterogeneity
Presenter: Christopher Chen
Session: Poster Display session 1
Resources:
Abstract
3569 - Clinical Benefit and Response Rate in Early Phase Clinical Trials: First Report from a Single-Institution Study
Presenter: Antonio Marra
Session: Poster Display session 1
Resources:
Abstract
4139 - Patient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): a single Phase I Unit experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract
4451 - Improving patient selection for immuno-oncology phase 1 trials: an external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O).
Presenter: Ghassan Al Darazi
Session: Poster Display session 1
Resources:
Abstract
1696 - Demonstrating the Changing Trends in Phase 1 Clinical Trials
Presenter: Christina Guo
Session: Poster Display session 1
Resources:
Abstract
3202 - Participation of Women in phase 1 oncology clinical trials
Presenter: Laura Vidal
Session: Poster Display session 1
Resources:
Abstract
4518 - Predictors for early trial discontinuation of patients with cancer participating in phase I clinical trials
Presenter: Joeri Douma
Session: Poster Display session 1
Resources:
Abstract
4368 - Safety of Tumor Treating Fields delivery to the torso: Meta analysis from TTFields clinical trials
Presenter: Federica Grosso
Session: Poster Display session 1
Resources:
Abstract
4615 - Proteomic Profiling Identifies Molecular Basis of Adverse Event to BPM31510 Exposure: Rationale for Comprehensive Molecular Pharmacodynamics (PD) in Phase 1 Clinical Trial Design
Presenter: Vivek Subbiah
Session: Poster Display session 1
Resources:
Abstract